Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Ipatasertib in Combination with Docetaxel for the Treatment of Non-small Cell Lung Cancer

Trial Status: closed to accrual

This phase II trial evaluates ipatasertib in combination with docetaxel for the treatment of small-cell lung cancer that has spread to other parts of the body (advanced/metastatic) and which has failed initial treatments. Ipatasertib is an enzyme inhibitor that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and can enhance the therapeutic effect of chemotherapy drugs such as docetaxel, which stops the growth of cancer cells either by killing the cells, stopping them from dividing, or stopping them from spreading.